RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Scancell Holdings Stock

Scancell Holdings Revenue 2024

Scancell Holdings Revenue

0 GBP

Ticker

SCLP.L

ISIN

GB00B63D3314

WKN

A1JZ3D

In 2024, Scancell Holdings's sales reached 0 GBP, a 0% difference from the 5.27 M GBP sales recorded in the previous year.

The Scancell Holdings Revenue history

YEARREVENUE (undefined GBP)GROSS MARGIN (%)
2026e--
2025e0.81587,87
2024e--
20235.2790,13
2022--
2021--
2020--
2019--
2018--
2017--
2016--
2015--
2014--
2013--
2012--
2011--
2010--
2009--
2008--
20072.18217,89
20060.0315833,33
20050.0147500,00

Scancell Holdings Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Scancell Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Scancell Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Scancell Holdings’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Scancell Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Scancell Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Scancell Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Scancell Holdings’s growth potential.

Scancell Holdings Revenue, EBIT and net profit per share

DateScancell Holdings RevenueScancell Holdings EBITScancell Holdings Net Income
2026e0 undefined-18.42 M undefined-16.51 M undefined
2025e808,000 undefined-13.28 M undefined-12.91 M undefined
2024e0 undefined-17.54 M undefined-17.8 M undefined
20235.27 M undefined-11.92 M undefined-11.94 M undefined
20220 undefined-14.26 M undefined-4.57 M undefined
20210 undefined-9.75 M undefined-15.48 M undefined
20200 undefined-6.78 M undefined-5.51 M undefined
20190 undefined-6.73 M undefined-5.63 M undefined
20180 undefined-4.94 M undefined-4.19 M undefined
20170 undefined-4.55 M undefined-3.54 M undefined
20160 undefined-3.04 M undefined-2.58 M undefined
20150 undefined-2.96 M undefined-2.41 M undefined
20140 undefined-2.5 M undefined-2.22 M undefined
20130 undefined-2.18 M undefined-1.9 M undefined
20120 undefined-1.96 M undefined560,000 undefined
20110 undefined-1.73 M undefined-1.65 M undefined
20100 undefined-1.81 M undefined-1.74 M undefined
20090 undefined-890,000 undefined-790,000 undefined
20080 undefined-510,000 undefined-410,000 undefined
20072.18 M undefined1.01 M undefined890,000 undefined
200630,000 undefined-730,000 undefined-640,000 undefined
200510,000 undefined-1.21 M undefined-1.05 M undefined

Scancell Holdings stock margins

The Scancell Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Scancell Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Scancell Holdings.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Scancell Holdings's sales revenue. A higher gross margin percentage indicates that the Scancell Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Scancell Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Scancell Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Scancell Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Scancell Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Scancell Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Scancell Holdings Margin History

Scancell Holdings Gross marginScancell Holdings Profit marginScancell Holdings EBIT marginScancell Holdings Profit margin
2026e90.13 %0 %0 %
2025e90.13 %-1,643.25 %-1,597.17 %
2024e90.13 %0 %0 %
202390.13 %-226.19 %-226.57 %
202290.13 %0 %0 %
202190.13 %0 %0 %
202090.13 %0 %0 %
201990.13 %0 %0 %
201890.13 %0 %0 %
201790.13 %0 %0 %
201690.13 %0 %0 %
201590.13 %0 %0 %
201490.13 %0 %0 %
201390.13 %0 %0 %
201290.13 %0 %0 %
201190.13 %0 %0 %
201090.13 %0 %0 %
200990.13 %0 %0 %
200890.13 %0 %0 %
200790.13 %46.33 %40.83 %
200690.13 %-2,433.33 %-2,133.33 %
200590.13 %-12,100 %-10,500 %

Scancell Holdings Aktienanalyse

What does Scancell Holdings do?

Scancell Holdings PLC is a biotechnology company specializing in the development of immunotherapies for cancer. The company was founded in 1997 and is headquartered in Nottingham, United Kingdom. Scancell's goal is to improve the lives of patients with cancer by developing innovative therapies that selectively activate the body's immune system. Scancell's business model is based on the research, development, and commercialization of immunotherapies. The company has developed a platform technology called Modified Vaccinia Ankara (MVA), which is a widely used virus in vaccine research and development. Scancell uses this platform technology to develop vaccines that selectively activate the immune system against cancer cells. The company works closely with academic partners and other biotech companies. The company has two main divisions: Scancell Immunotherapy and Scancell Biotherapeutics. Under the Scancell Immunotherapy division, the company develops cancer vaccines. Scancell is actively working on the development of two main products: SCIB1 and Modi-1. SCIB1 is an immunotherapy based on a DNA-based vaccine that activates the immune system to attack cancer cells. This vaccine has been studied in various clinical trials and has shown promising results. SCIB1 has been tested in a Phase II study on patients with advanced melanoma and has triggered a strong immune response in most patients. The company is now working on further developing SCIB1 in clinical trials. Modi-1 is an immunotherapy based on a novel technology called Modified T-cells. These are engineered T-cells that compel the immune system to recognize and attack cancer cells. Modi-1 is still in the development phase and has not yet been tested in clinical trials. Under the Scancell Biotherapeutics division, the company develops antibodies for cancer treatment. The company focuses on developing antibodies that target specific cancer antigens. Scancell has already developed several promising antibody candidates, including AvidiMabTM, an antibody candidate against the CD98 receptor, which is overexpressed in many cancer cells. Scancell is currently listed on the London Stock Exchange and has a market capitalization of around £250 million. The company also has a strong pipeline of products in development and is actively working to realize their potential. Scancell has a strong partnership with AstraZeneca, one of the world's largest pharmaceutical companies, to support its research and development activities. In summary, Scancell is an emerging biotech company specializing in the development of immunotherapies for cancer. The company has a strong pipeline of products in development and works closely with leading scientists and academic institutions. Scancell is a promising company that offers exciting opportunities for both investors and patients. Scancell Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Scancell Holdings's Sales Figures

The sales figures of Scancell Holdings originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Scancell Holdings’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Scancell Holdings's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Scancell Holdings’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Scancell Holdings stock

How much revenue did Scancell Holdings generate this year?

Scancell Holdings has achieved a revenue of 0 GBP this year.

How much was the turnover of the company Scancell Holdings compared to the previous year?

The revenue of Scancell Holdings has increased by 0% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Scancell Holdings?

The revenue of Scancell Holdings is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Scancell Holdings measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Scancell Holdings so important for investors?

The revenue of Scancell Holdings is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Scancell Holdings pay?

Over the past 12 months, Scancell Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Scancell Holdings is expected to pay a dividend of 0 GBP.

What is the dividend yield of Scancell Holdings?

The current dividend yield of Scancell Holdings is .

When does Scancell Holdings pay dividends?

Scancell Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Scancell Holdings?

Scancell Holdings paid dividends every year for the past 0 years.

What is the dividend of Scancell Holdings?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Scancell Holdings located?

Scancell Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Scancell Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Scancell Holdings from 9/29/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Scancell Holdings pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Scancell Holdings in the year 2023?

In the year 2023, Scancell Holdings distributed 0 GBP as dividends.

In which currency does Scancell Holdings pay out the dividend?

The dividends of Scancell Holdings are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Scancell Holdings

Our stock analysis for Scancell Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Scancell Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.